SCHEMBL4894331

SCHEMBL4894331

N#Cc1cccc(S(=O)(=O)F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCOLN3 Q8TDD5 1/20 0.51
NR1H3 Q13133 1/20 0.48
KAT6A Q92794 2/20 0.48
ACLY P53396 2/20 0.47
PGR P06401 1/20 0.47
ENPP2 Q13822 1/20 0.46
RORC P51449 1/20 0.45
CTSG P08311 1/20 0.44
CMA1 P23946 1/20 0.44
GLO1 Q04760 1/20 0.44
SLC40A1 Q9NP59 1/20 0.44
GRM5 P41594 1/20 0.44
CA12 O43570 3/20 0.43
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
CA9 Q16790 3/20 0.43
CA14 Q9ULX7 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
HSPD1 P10809 1/20 0.41
PTPN2 P17706 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17161327 0.82 CA2 (0.44) MCOLN3NR1H3KAT6AACLYCA12
SCHEMBL1891657 0.82 MCOLN3 (0.49) MCOLN3NR1H3KAT6AACLYPGR
SCHEMBL65861 0.80 ENPP2 (0.50) MCOLN3NR1H3KAT6AACLYPGR
SCHEMBL30915555 0.80 MCOLN3 (0.51) MCOLN3NR1H3KAT6AACLYPGR
SCHEMBL4574069 0.80 KAT6A (0.48) MCOLN3NR1H3KAT6AACLYPGR
SCHEMBL791765 0.80 CA2 (0.67) MCOLN3PGRCA12CA1CA2
SCHEMBL1487652 0.80 TSHR (0.52) MCOLN3NR1H3KAT6AACLYPGR
SCHEMBL410063 0.80 MCOLN3 (0.51) MCOLN3NR1H3KAT6AACLYPGR
SCHEMBL2223665 0.79 MCOLN3 (0.62) MCOLN3NR1H3ACLYPGRRORC
SCHEMBL29602415 0.79 EPAS1 (0.59) MCOLN3NR1H3KAT6AACLYPGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318933-A1 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders GLAXO GROUP LIMITED 2008-12-25 US disclosed
EP-1814873-A2 5-SULFONYL-1-PIPERIDINYL SUBSTITUTED INDOLE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS GLAXO GROUP LIMITED (GB) 2007-08-08 EP disclosed
WO-2006038006-A2 5-SULFONYL-1-PIPERIDINYL SUBSTITUTED INDOLE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS GLAXO GROUP LIMITED (GB) 2006-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318933-A1 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders HTR6, HTR5A, TPH1 MCOLN3 1609/4885NR1H3 946/4885KAT6A 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.